IL23A抗体;IL23A Antibody—艾普蒂 新品

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Jurkat cell lysate, Primary antibody: P13338(IL23A Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13338(IL23A Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

IL-23A antibodies target the p19 subunit of interleukin-23 (IL-23), a pro-inflammatory cytokine implicated in autoimmune and chronic inflammatory diseases. IL-23. composed of the unique p19 subunit and a shared p40 subunit (also part of IL-12), binds to its receptor (IL-23R) on immune cells, particularly T helper 17 (Th17) cells, driving their differentiation and production of inflammatory mediators like IL-17 and IL-22. Dysregulated IL-23 signaling is linked to pathologies such as psoriasis, inflammatory bowel disease (IBD), and ankylosing spondylitis.

Therapeutic IL-23A antibodies selectively block the p19 subunit, disrupting IL-23-mediated inflammation without affecting IL-12 (which shares p40). This specificity reduces off-target effects compared to dual IL-12/IL-23 inhibitors. Clinically approved anti-IL23A biologics, such as risankizumab and guselkumab, are monoclonal IgG antibodies engineered for high affinity and extended half-life. They demonstrate efficacy in moderate-to-severe plaque psoriasis and are being explored for IBD and other IL-23-driven conditions. By neutralizing IL-23A, these antibodies suppress Th17 pathways, attenuating tissue inflammation while preserving broader immune functions. Ongoing research aims to optimize delivery, durability, and safety profiles, solidifying IL-23A as a pivotal therapeutic target in precision immunology.